Product Data SheetProduct Name:CAS No.: Cat. No.:MWt:Formula:Purity :Mifamurtide83461-56-7HY-136821237.50C59H109N6O19P>98%Solubility:DMSOMechanisms: Pathways:Others; Target:Others gyBiological Activity:Mifamurtide(CGP19835; MTP-PE) is a drug against osteosarcoma. Target: Others Mifamurtide is an immunomodulator with antitumor effects that appear to be mediated via activationof monocytes and macrophages. Mifamurtide is generally well tolerated; adverse events attributed toadministration of the drug include chills, fever, headache, nausea, and myalgias. Based on theavailable data, mifamurtide can be considered for inclusion in treatment protocols for localizedosteosarcoma [1]. Mifamurtide has orphan drug status for the treatment of osteosarcoma in the US[] and EU [2].References:[1]. Frampton, J.E., Mifamurtide: a review of its use in the treatment of osteosarcoma. PaediatrDrugs, 2010. 12(3): p. 141-53. [2]. Mifamurtide: CGP 19835, CGP 19835A, L-MTP-PE, liposomal MTP-PE, MLV 19835A, MTP-PE,muramyltripeptide phosphatidylethanolamine. Drugs R D, 2008. 9(2): p. 131-5.yppppyg()p Caution: Not fully tested. For research purposes onlyMedchemexpress LLCwww.medchemexpress.com18Wilkinson Way, Princeton, NJ 08540,USAess.com Web: www.medchemexpress.comEmail: info@medchemexpr
